3SOF

Quote from: IdFix on October 26, 2006, 03:21:25 AM
Melf...if you haven't sold...
Today will be the day I think ( 1.54 in play ? we'll see!...)
Have a look :

Id,

I've been hanging on...by a fingernail.    My 1.25 stop wasnt' hit.

Quote
"I am excited to be joining the highly talented and innovative team at ITP and look forward to making significant contributions to the continued success of Insmed Inc.," said Mr. Farrar.

Let's hope that the market gets as excited as Mr. Farrar. 

Thanks for that new, Id.  Applaud.

Hi guys'
FYI..


Insmed to Present at Upcoming Conferences
Monday October 30, 4:56 pm ET


RICHMOND, Va.--(BUSINESS WIRE)--Insmed Incorporated (NASDAQ: INSM - News) today announced that Philip J. Young, Chief Business Officer of Insmed Incorporated, will present a corporate overview on Tuesday, October 31 at 10:30 AM ET during the C.E. Unterberg, Towbin Life Sciences Conference taking place at the New York Palace Hotel in New York City. He will also be presenting on Monday, November 6 at 4:55 PM ET at the Rodman & Renshaw 8th Annual Healthcare Conference at the New York Palace Hotel in New York City; and on Tuesday, November 28 at 9:30 AM ET at the Lazard Capital Markets 3rd Annual Life Sciences Conference, which is also taking place at the New York Palace Hotel in New York City

----------------------------------------------------------
http://www.fbo.gov/servlet/Documents/R/1573013

General Information


Document Type:  Award Notice
Solicitation Number:
Posted Date: Oct 30, 2006
Archive Date: Oct 30, 2006
Classification Code: 65 -- Medical, dental & veterinary equipment & supplies
SetAsides: 
Naics Code: N/A 

Contracting Office Address
Attn: Department of Veterans Affairs National Acquisition Center, (049A1), P.O. Box 76, Building No. 37, Hines, Illinois 60141
Description
Contract Award Date: Jun 09, 2006
Contract Award Number: V797P-5906X
Contract Award Amount: $7,500,000
Contract Line Item Number:
Contractor: Insmed Incorporated, 4851 Lake Brook Dr., Glen Allen, Virginia, 23060

--------------------------------------------------------------

Today...

Jody LoMenzo Named Director, Investor Relations and Corporate Communications
Tuesday October 31, 8:15 am ET


RICHMOND, Va.--(BUSINESS WIRE)--Insmed, Inc. (NASDAQ:INSM - News) announced today that Jody M. LoMenzo has joined the company to serve as Director, Investor Relations and Corporate Communications.
ADVERTISEMENT


Over the course of her professional career, Ms. LoMenzo has served in senior communications roles for Fortune companies, start-ups, and non-profits, including: the medical-surgical division of McKesson Inc. as marketing communications director; United Dominion Realty Trust, as director of investor relations and corporate communications; Infineon Technologies (White Oak Semiconductor) as communications director; and as administrative director for marketing and public relations at Bon Secours Richmond Health System.

Ms. LoMenzo also has experience on the agency side, working as director of strategic communications for the public relations division of The Martin Agency. She owned and operated her own communications strategy firm, working with healthcare clients in biotechnology and pharmaceuticals to introduce and promote new drugs. Of note, her work with Genentech for the launch of tPA, SmithKline for its Hivagen test, Amgen for Neupogen, Fujisawa for Ganite, BristolMeyer-Squibb for Cardio Tec, Sandoz for Eldyprl, and Lederle for Suprax.

Ms. LoMenzo began her professional career in television, working in New York City, as a news editor for ABC-TV's Good Morning America and as associate producer at CBS News. She received an Emmy nomination while at WABC-TV for her work as special projects producer. A graduate of New York University, she resides in Richmond.

----------------------------------------------------

Sthg is on...let INSM fly now !!!!!

----------------------------------------------------

Id.....

Quote from: Melf Elf on October 26, 2006, 08:23:20 AM

Quote from: IdFix on October 26, 2006, 03:21:25 AM
Melf...if you haven't sold...
Today will be the day I think ( 1.54 in play ? we'll see!...)
Have a look :

Id,

I've been hanging on...by a fingernail.    My 1.25 stop wasnt' hit.

Sold INSM for a break even. 

Id Fix,

Thanks for the updates.   Applause. 

Quote

Quote

Quote from: Melf Elf on November 01, 2006, 10:27:14 AM
[
I've been hanging on...by a fingernail.    My 1.25 stop wasnt' hit.

Sold INSM for a break even. 

It turns out that my 1.25 got hit today, and I woulda have had a 6% loss instead of the break even I took yesterday.

That's a coulda...shoulda...woulda that turned out okay. 

hi,

The third International Congress of the GRS and the IGF society
http://www.congre.co.jp/3grs-igf/

Exhibitors List :

E-1 Pfizer
E-2 Insmed
E-3 Eli Lilly and Company
E-4 Novo Nordisk Pharma
E-5 Serono International
E-6 Dainippon Sumitomo Pharma

Re: Info Coup
That's it, but inside...

The week of November 11 or the next may great us with a bombardment of good news! Fasten your seat belts! This is just a sampling with the relevant new formulation of iPlex and the Cecilia Camacho-Hübner study. I've also thrown in some Clemmon's March info. There are sevral more BP3 study presentations, but I leave that for all of you to read...the first link is the goody. Enjoy!

http://www.congre.co.jp/3grs-igf/images/program.pdf
PO14 IGF Clinical/Therapy
LP-92 Stability of rhIGF-I/rhIGFBP-3 under common storage conditions Kenneth M. Attie Dept. of Medical Affairs, Insmed Inc., Richmond, VA,
USA

OR08-4 The IGFBP-3 partner, humanin, protects beta cells from apoptosis in vitro and improves glucose tolerance in the NOD model in vivo Kuk-Wha Lee Department of Pediatric Endocrinology, Mattel Children's Hospital at University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, USA

OR08-3 Effects of insulin-like growth factor binding protein-3 on human malignant pleural mesothelioma cell growth and apoptosis Cecilia Camacho-Hübner Department of Endocrinology, William Harvey Research Institute and St Bartholomew's Hospital, University of London, London, UK

http://grc.org/programs/2007/insulin.htm

David Clemmons a Lead investigator for Insmed...diabetes

Re: Info Coup

No takers on the OR08-4 presentation?

"IGFBP-3 partner, humanin, protects beta cells from apoptosis in vitro and improves glucose tolerance in the NOD model"

If IGFBP-3 "holds" humanin for delivery...Alzheimer's
http://www.pepnet.com/humanin.html


Therefore: a lot of interesting news: as you can see the Alzheimer stuff is still in mice tests just like the Herceptin/BP3 Breastcancer tests discussed here a couple of months ago. But again it's a sign of the possibilities INSMEDs product portfolio brings.
Also: nice to see that INSMED is exhibiting between big guns in pharma, it's a recognition of the eminent work done by INSM in the field.




Id

Id,

I would wait for the CCI to give a buy signal first before considering it.  All in all INSM still has a bearish tone and a lot of uncertainty in the air.  I am waiting for INSM to show me something positive, rather than try and pick a bottom for now.

agreed Scott.
...
I have the time with this one...
and am bit nervous also....When The freakin jury's trial will be ended...the stock will move, perhaps before if you read what I post...
Buy on rumors...sell on news ?

IdFix

nice move at the end. with huge volume. resolution to the trial..we shall see.

Id,

dunno what happened there, but you were bang on the money - hope you got some!!!

Hi,

Good volume again on friday,(is sthg on ??)

10-Nov-06 1.28 1.35 1.24 1.33 3,203,900 1.33

9-Nov-06 1.35 1.38 1.25 1.28 1,638,100 1.28

8-Nov-06 1.20 1.40 1.19 1.37 2,647,400 1.37

7-Nov-06 1.21 1.24 1.19 1.19 809,900 1.19

6-Nov-06 1.25 1.28 1.18 1.22 1,607,600 1.22

---------------------------------------

INSM was presenting on November 11th at Kobe , Japan their new room stable form of iPlex. ....
+ end of jury's trial expected on 22/11..

--> this could be really interesting ...MMMmmh
We'll see !

-----------------------------------------



-------Id...

Id,

I like it, Volume is always a very good sign of something cooking.  A close above 1.36 would suggest INSM is finally ready to break out.  As we all know, any number of news related factors could propel this one significantly upward.

I may look to enter a position on Monday.

Cheers for keeping the INSM thread on the boil!

INSM is on fire and I like it!!!

Has broken out of the recent falling wedge and has got above 1.47-1.48 resistance.  A close above here would bode very well.  I am not sure whether this is related to the trial or what, but I like it and am back in.  Averaged in at 1.45.  First target, 1.60.

Not such a great close, at 1.46, INSM couldn't hold onto its earlier gains.  However, 1.50 was broken and I think we will be back there shortly, and the long term chart suggests 1.45 should be support.  Upcoming resistance at 1.54-55, and 1.65.  Volume is still very solid, above 3m, I think she finally wants to move.  Really any news pending the trial could kick this one off, and the 1 yr chart shows clear potential. 

INSM can be volatile, so I will go with a 1.29 stop for now, just below the upper trendline of the flag and the 50SMA.  This quite a bit of risk for this trade, so I will look to move it up if we get support confirmation at 1.35 or 1.40.  The flag breakout puts a target of 1.70 in play.

Here is a 1 yr semi-log chart:

INSM update:

Following the breakout of the recent falling wedge pattern, INSM rallied up to the pattern resistance at 1.54 and has pulled back the last couple of days, also tagging 1.35, confirming this level as support within the current move.  Fridays candle suggest some indecision in the market on INSM, but the falling wedge target of 1.70 is still in play provided the pattern brekout level holds at 1.34.  Looking at the 30 minute chart, there is also a recent ascending trendline forming with 3 tags, that may support further advances.  Volume in the last 2 weeks is also up significantly, with big volume on the up moves and low volume on the pullbacks, which is provides encouragment that INSM has legs to go further.

I'm beginning to think that INSM is potentially a very high risk play right now, as pretty much everything hinges on what happens in the patent infringement case.  From what I have read, it appears that INSM has a fairly strong chance on winning at least some of the patent issues - whether they will come out with a clean sheet remains to be seen.  In any case, I am trying to be more risk averse in my trading, so I may sell a portion of my position if I can get a price above 1.45 in the next day or 2, simply to limit the risk.  The stop for my position will be set at 1.33, giving me just over 8% risk on the trade, barring any gap down.  the chart looks quite positive right now, but with heavily news driven stocks like this (and we know what bad news does), anything can happen.

Big move for INSM today, 1.70 falling wedge target MADE.  Looks good - it seems this must be related to expectations surroundinga positive resolution of the trial.  I'm holding my position for now.